These data suggest that Tnfrsf4 may serve as a target to selectively eliminate/inactivate Tregs in CML without directly affecting CD8+ CTL–mediated immunity and leukemia cells. The gene discussed is TNFRSF4; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.